Co-evaluation of the two astrocytic immuno-markers revealed more than 50% of the 1p/19q non-codeleted oligodendroglial tumors did not show p53 positivity and ATRX loss, i.e. they were not molecularly astrocytic. The gene discussed is TP53; the disease is oligodendroglial tumor.